Overall verdict
Buy
7.7/10
1-year performance
+16.82%
Score breakdown
Up 16.8% over 1 year, 58% of the 52-week range.
Strongest: Profitability 10.0/10. Weakest: Valuation 5.3/10.
12 analysts, target +0.3% vs the price.
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions.
In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
Sector
Health Care
Industry
Health Care Providers and Services
Primary listing
Nasdaq
United States
CEO
Peter Anevski
Founded
2008
Employees
856
Revenue / employee
1.5M USD
Next earnings
November 6, 2026 (estimated)
Institutional holders
- BlackRock, Inc.15.14%
- FMR LLC9.14%
- VANGUARD PORTFOLIO MANAGEMENT LLC6.55%
- VANGUARD CAPITAL MANAGEMENT LLC4.19%
- STATE STREET CORP3.95%
- AMERIPRISE FINANCIAL INC3.61%
- FORT WASHINGTON INVESTMENT ADVISORS INC /OH/3.33%
- CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM3.12%
- GEODE CAPITAL MANAGEMENT, LLC2.57%
- Other institutions54.51%
310 13F filings as of June 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
33.06 USD
52-week low
16.10 USD
1-year performance
16.82%
Rising
Year-to-date performance
0.74%
Rising
Drawdown
-21.76%
Marked drawdown
Position in the 52-week range
58% of range
Range: 25.06 USD - 26.80 USD (comparables only)
The price implies growth of -2.76% per year; the company grows at 6.78%.
Quality and profitability
10.0/10Gross margin 24.6%, net margin 6.0%, ROIC 15.5%, ROE 16.2%.
Net margin
6.00%
Exceptional
Sector 0.88%|S&P 12.97%
Gross margin
24.57%
High
Return on equity (ROE)
16.24%
Exceptional
Sector 8.69%|S&P 16.52%
Return on invested capital (ROIC)
15.47%
Exceptional
Free cash flow margin (FCF)
13.61%
Exceptional
Profit-to-cash conversion (FCF conversion)
2.27x
Exceptional
Margin stability
11.0 pts
Very uneven
Revenue to net income
Growth
8.7/10Revenue up 5.3% over 1 year, 30.2% a year over 5, EPS 6.8% a year over 5.
Revenue (trailing 12 months)
1.3Md USD
Revenue growth (1y)
5.30%
Moderate
Revenue growth (3y)
63.76%
Strong
EPS growth (1y)
78.89%
Hyper-growth
EPS CAGR (5y)
6.78%
Low
EPS revisions (3 months)
1.26%
Revised up
Valuation
5.3/10P/E 28.1x, forward P/E 20.1x, EV/EBITDA 15.0x, PEG 4.14. The multiple sits in the 31th percentile of its own 5-year history.
P/E (TTM)
28.1x
Fair
Sector 28.1x|S&P 23.0x
Forward P/E
20.1x
Fair
EV / EBITDA
15.0x
Fair
Sector 15.7x|S&P 14.5x
PEG
4.14
Very expensive
Sector 1.30|S&P 0.86
Fair value (reverse DCF)
25.93 USD
Fairly priced
P/E vs its own 5-year history
among the 31% lowest valuations
Cheaper than usual
Market cap
2.0Md USD
Financial strength
10.0/10Cash covers 878.5% of the debt, net debt/EBITDA -3.1x.
Net debt / EBITDA
-3.1x
Net cash
Gearing (net debt / equity)
-46.32%
Net cash
Cash
237M USD
Cash / market cap
11.95%
Solid
Cash / total debt
878.48%
Net cash
Net debt
-210M USD
Equity
453M USD
Closed daily candles, 2 years
Last close on September 24, 2026: 25.97 USD
- MM2026.63
- MM5028.01
- MM20024.22
- RSI 1440.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+0.84%
200-day average slope, 3 months
+9.32%
50-day average slope, 1 month
-3.50%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
1.73 % per day
Volatility change
-32.25%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 1.29 (10) | 2.08 (9) | 1 375 (11) | 237 (10) | 106 (11) |
| 2027 | 1.52 (10) | 2.32 (9) | 1 512 (11) | 265 (10) | 125 (11) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 8, 2026.
Same sub-industry: 10 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | PGNY | 7.7 | 8.1 | 2.0Md USD | 28.1x | 6.0 % | 5.3 % | 15.5 % | -3.1x | 9.0 % | 16.8 % | ||
| 2 | SAUD3 | 7.5 | 6.6 | 8.0Md USD | 14.3x | 10.6 % | 1213.1 % | 10.4 % | -0.3x | 1.6 % | 5.3 % | ||
| 3 | UNH | 7.5 | 7.0 | 333Md USD | 23.9x | 3.1 % | 0.4 % | 8.4 % | 1.9x | 7.1 % | 7.1 % | ||
| 4 | HQY | 7.3 | 7.0 | 7.5Md USD | 32.6x | 17.4 % | 7.6 % | 7.7 % | 1.4x | 6.5 % | -5.7 % | ||
| 5 | ELV | 6.8 | 6.0 | 86.4Md USD | 17.7x | 2.5 % | 1.4 % | 6.7 % | — | 7.3 % | 22.7 % | ||
| 6 | HUM | 6.0 | 4.9 | 45.0Md USD | 35.5x | 0.9 % | 26.2 % | 4.1 % | -1.9x | 4.3 % | 47.6 % | ||
| 7 | CNC | 5.9 | 4.9 | 30.7Md USD | Not meaningful (loss) | -2.5 % | 9.9 % | -12.2 % | 1.5x | 29.2 % | 89.2 % | ||
| 8 | CLOV | 4.8 | 3.8 | 2.4Md USD | Not meaningful (loss) | -0.7 % | 55.6 % | -5.1 % | 3.5x | 3.1 % | 38.3 % | ||
| 9 | MOH | 4.4 | 2.5 | 9.9Md USD | Not meaningful (loss) | -0.0 % | -4.8 % | -0.1 % | -20.7x | 2.7 % | 6.0 % |
